There is currently no text in this page. You can search for this page title in other pages, or search the related logs, but you do not have permission to create this page.
Category:C12N15/113
Jump to navigation
Jump to search
Subcategories
This category has the following 130 subcategories, out of 130 total.
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
V
W
X
Y
Z
Pages in category "C12N15/113"
The following 126 pages are in this category, out of 126 total.
1
- 18007439. GENE CORRECTION FOR SCID-X1 IN LONG-TERM HEMATOPOIETIC STEM CELLS simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)
- 18187102. Compositions and methods for improved malonyl-CoA biosynthesis using 2-stage dynamic metabolic control simplified abstract (Duke University)
- 18248988. NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR simplified abstract (SANOFI)
- 18251227. SIRNA-NANOBOWL-MEDIATED INTERVENTION OF COVID-19 simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18270014. Suppression-Replacement Gene Therapy simplified abstract (Mayo Foundation for Medical Education and Research)
- 18273716. METHODS FOR TREATING AND AMELIORATING CANCER simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18274133. PHOTO-CROSSLINKED BIOREDUCIBLE POLYMERIC NANOPARTICLES FOR ENHANCED RNA DELIVERY (The Johns Hopkins University)
- 18280126. METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)
- 18286984. PROMOTERS FOR VIRAL-BASED GENE THERAPY (The Regents of the University of California)
- 18289921. METHODS AND COMPOSITIONS FOR TREATING EPILEPSY (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
- 18323956. REPROGRAMMING OF NON-NEURONAL CELLS INTO NEURONS AND METHODS AND COMPOSITIONS TO TREAT NEURODEGENERATIVE DISEASES AND DISORDERS simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18402154. SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE simplified abstract (Duke University)
- 18421326. Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18449940. DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS simplified abstract (Massachusetts Institute of Technology)
- 18463589. TARGETED NON-VIRAL DNA INSERTIONS simplified abstract (The Regents of the University of California)
- 18487429. SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER simplified abstract (Board of Regents, The University of Texas System)
- 18501859. Methods and Compositions for Treating, Ameliorating, and/or Preventing Chronic Kidney Disease (CKD) and Complications thereof by Regulating DPEP1, CASP9, ACSS2 and/or FASN simplified abstract (The Trustees of the University of Pennsylvania)
- 18503125. SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER simplified abstract (Board of Regents, The University of Texas System)
- 18544247. GENE THERAPY TREATMENT OF ATRIAL FIBRILLATION simplified abstract (NORTHWESTERN UNIVERSITY)
- 18559667. PRODUCTION OF THERAPEUTIC MESENCHYMAL STEM CELL-DERIVED EXOSOMES simplified abstract (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM)
- 18575450. TARGETING PIEZO1 TO TREAT INHERITED AND AGE-RELATED MACULAR DEGENERATIONS simplified abstract (The Regents of the University of California)
- 18577881. METHODS OF CONTROLLING RNA BINDING PROTEIN ACTIVITY simplified abstract (The Regents of the University of California)
- 18602410. IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY simplified abstract (The Board of Trustees of the Leland Stanford Junior University)
- 18608561. METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18618604. RNA EDITING simplified abstract (HOFFMANN-LA ROCHE INC.)
- 18659737. COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING simplified abstract (Northwestern University)
- 18668366. MICROPEPTIDES AND USE OF SAME FOR MODULATING GENE EXPRESSION simplified abstract (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
- 18675023. OLIGONUCLEOTIDES FOR TISSUE SPECIFIC GENE EXPRESSION MODULATION (University of Massachusetts)
- 18684960. PEPTIDE-BINDING HYBRID LIPOSOME EXOSOME, PEPTIDE-BINDING EXOSOME, COMPOSITION CONTAINING SAME, AND METHOD OF FORMING SAME (SEKISUI CHEMICAL CO., LTD.)
- 18688144. DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES (Massachusetts Institute of Technology)
- 18709695. IRAP INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
- 18725289. IONIZABLE LIPIDS FOR MULTIPLE ORGAN TARGETING (Massachusetts Institute of Technology)
- 18735668. ANTISENSE OLIGONUCLEOTIDES TARGETING ACTL6B simplified abstract (Hoffmann-La Roche Inc.)
- 18742639. ORAL CODELIVERY OF 5-FLUOREURACIL AND Bcl2 siRNA TREATING STOMACH CANCER (Board of Regents, The University of Texas System)
- 18742746. ORAL CODELIVERY OF NAVITOCLAX AND Bcl2 siRNA TREATING GASTIC CANCER (Board of Regents, The University of Texas System)
- 18744136. TIS-L TARGETING ANTIVIRAL ANTISENSE OLIGONUCLEOTIDE WITH ABILITY TO INHIBIT VIRAL REPLICATION OF SARS-COV-2 (KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY)
- 18749156. THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF simplified abstract (HOFFMANN-LA ROCHE INC.)
- 18751096. THERAPEUTIC TREATMENT FOR FRAGILE X-ASSOCIATED DISORDER (University of Massachusetts)
- 18751730. Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18764835. Compositions and Methods for Modulating Single Stranded DNA Regions that Catalyze Enzymatic Reactions (The Trustees of the University of Pennsylvania)
- 18782680. METHODS OF MODULATING RNA TRANSLATION (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18885092. COMPOUND AND LIPID COMPOSITION (FUJIFILM Corporation)
- 18907274. COMPOSITIONS AND METHODS USEFUL IN PROMOTING MILK PRODUCTION (The Regents of the University of California)
- 18942238. METHODS FOR THE TREATMENT OF NLRP3 RELATED DISORDERS (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18956207. RIBOZYME-ASSISTED CIRCULAR RNAS AND COMPOSITIONS AND METHODS OF USE THEREOF (MASSACHUSETTS INSTITUTE OF TECHNOLOGY)
- 18962390. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (MASSACHUSETTS INSTITUTE OF TECHNOLOGY)
2
A
- AMGEN INC. (20250011779). COMPOSITIONS AND METHODS FOR ENHANCING GENE SILENCING ACTIVITY OF OLIGONUCLEOTIDE COMPOUNDS
- Arrowhead Pharmaceuticals, Inc. (20250092072). Trialkyne Linking Agents and Methods of Use
- AstraZeneca Ireland Limited (20250002908). COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT COMPONENT 3 EXPRESSION
B
- Biotechnology patent applications on 21st Mar 2025
- Biotechnology patent applications on 7th Mar 2025
- Biotechnology patent applications on January 2nd, 2025
- Biotechnology patent applications on June 27th, 2024
- Biotechnology patent applications on March 20th, 2025
- Biotechnology patent applications on March 6th, 2025
- Biotechnology patent applications on May 30th, 2024
- Biotechnology patent applications on November 14th, 2024
- Biotechnology patent applications on September 5th, 2024
- Blockchain patent applications on April 11th, 2024
- Blockchain patent applications on April 4th, 2024
- Blockchain patent applications on February 1st, 2024
- Blockchain patent applications on February 29th, 2024
- Blockchain patent applications on January 25th, 2024
- Blockchain patent applications on March 28th, 2024
- BRCA1 patent applications on January 16th, 2025
C
- Celex Oncology Innovations Limited (20250092399). GENE THERAPY TARGETING THE NEONATAL FORM OF NAV1.5 FOR TREATING CANCER
- CHARLES RIVER LABORATORIES, INC. (20240294943). METHOD FOR IMPROVING GENETIC ENGINEERING OF ADOPTIVE CELL THERAPIES simplified abstract
- CHINESE PLA GENERAL HOSPITAL (20250002911). Engineered Exosome for Treating Hypertrophic Scar (Hts), and Preparation Method and Use Thereof
D
- DNA Storage patent applications on 14th Feb 2025
- DNA Storage patent applications on 14th Mar 2025
- DNA Storage patent applications on 21st Feb 2025
- DNA Storage patent applications on 21st Mar 2025
- DNA Storage patent applications on 28th Feb 2025
- DNA Storage patent applications on February 13th, 2025
- DNA Storage patent applications on February 20th, 2025
- DNA Storage patent applications on February 27th, 2025
- DNA Storage patent applications on February 6th, 2025
- DNA Storage patent applications on January 16th, 2025
- DNA Storage patent applications on January 23rd, 2025
- DNA Storage patent applications on January 2nd, 2025
- DNA Storage patent applications on January 30th, 2025
- DNA Storage patent applications on January 9th, 2025
- DNA Storage patent applications on March 13th, 2025
- DNA Storage patent applications on March 20th, 2025
- Dyne Therapeutics, Inc. (20250066495). MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MUSCULAR DYSTROPHY
- Dyne Therapeutics, Inc. (20250066496). MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
F
I
S
- SAREPTA THERAPEUTICS, INC. (20250011777). DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES
- Secarna Pharmaceuticals GmbH & Co. KG (20250059547). NLRP3 oligonucleotide for use in preventing and/or treating an inflammatory disease
- SHANDONG UNIVERSITY (20250019707). ANTISENSE OLIGONUCLEOTIDE FOR REGULATING BCL2L12 EXPRESSION AND THE USE THEREOF IN TREATMENT OF DISEASES
- Sumitomo Pharma Co., Ltd. (20250084411). Antisense Nucleic Acid
- SynerK Biotech Limited (20240376476). NUCLEIC ACID TARGETING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 AND USES THEREOF simplified abstract
T
- The regents of the university of california (20240336918). METHODS OF CONTROLLING RNA BINDING PROTEIN ACTIVITY simplified abstract
- The regents of the university of california (20250002920). GENETIC MODIFICATION OF MAMMALIAN CELLS TO CONFER RESISTANCE TO CSF1R ANTAGONISTS
- The regents of the university of california (20250064808). METHODS FOR THE TREATMENT OF NLRP3 RELATED DISORDERS
- The regents of the university of california (20250092129). COMPOSITIONS AND METHODS USEFUL IN PROMOTING MILK PRODUCTION
- The regents of the university of california (20250092391). PROMOTERS FOR VIRAL-BASED GENE THERAPY
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA patent applications on February 27th, 2025
- The Regents of the University of California patent applications on January 2nd, 2025
- The Regents of the University of California patent applications on March 20th, 2025
- The Regents of the University of California patent applications on October 10th, 2024
- The Trustees of Columbia University in the City of New York (20240294643). COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESS simplified abstract
- THIRD INSTITUTE OF OCEANOGRAPHY, MNR (20250092161). PROMOTION SYSTEM FOR CELLULAR PROTEIN SYNTHESIS AND USE THEREOF
U
- University Of Cincinnati (20250002915). MOLECULAR THERAPEUTICS FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND HEART FAILURE ASSOCIATED WITH MYBPC3 GENE MUTATIONS
- UNIVERSITY OF MASSACHUSETTS (20240209376). Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons simplified abstract
- University of Massachusetts (20250066780). OLIGONUCLEOTIDES WITH INTERNUCLEOTIDE LINKAGE MODIFICATIONS FOR KIDNEY TARGETING
- University of Rochester (20250019702). GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY
- Unknown Organization (20250019709). NOVEL OXO-RNA COMPOSITIONS AND THE RELATED APPLICATIONS THEREOF
- US Patent Application 18334046. TYPE VI CRISPR ORTHOLOGS AND SYSTEMS simplified abstract
V
- VIB VZW (20240294931). Means and Methods for Improved Regeneration simplified abstract
- VIB VZW (20250011793). Oligonucleotides for Modulating Synaptogyrin-3 Expression
- VICO Therapeutics B.V. (20250011784). RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
